Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group
| Autor: | Teresa Halbsguth, Bastian von Tresckow, Michael Fuchs, Peter Borchmann, Dennis A. Eichenauer, Jeremy Franklin, Achim Rothe, Andreas Engert, Indra Thielen, Beate Klimm, Stephanie Sasse, Volker Diehl, Boris Böll, Heinz Haverkamp, Karolin Behringer |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Adolescent Immunology Therapy-Related Acute Myeloid Leukemia Biochemistry Bleomycin Young Adult immune system diseases hemic and lymphatic diseases Internal medicine Germany Antineoplastic Combined Chemotherapy Protocols medicine Humans In patient Cyclophosphamide Aged Etoposide Retrospective Studies business.industry Myelodysplastic syndromes Incidence (epidemiology) Incidence Hematopoietic Stem Cell Transplantation Myeloid leukemia Neoplasms Second Primary Cell Biology Hematology Middle Aged medicine.disease Prognosis Hodgkin Disease Survival Rate Leukemia Myeloid Acute Doxorubicin Vincristine Myelodysplastic Syndromes Procarbazine Hodgkin lymphoma Prednisone Female business Follow-Up Studies |
| Zdroj: | Blood. 123(11) |
| ISSN: | 1528-0020 |
| Popis: | Therapy-related acute myeloid leukemia and myelodysplastic syndromes (t-AML/MDS) represent severe late effects in patients treated for Hodgkin lymphoma (HL). Because more recent data are scarce, we retrospectively analyzed incidence, outcome, and risk factors for the development of t-AML/MDS after HL. A total of 11,952 patients treated for newly diagnosed HL within German Hodgkin Study Group trials between 1993 and 2009 were considered. At a median follow-up of 72 months, t-AML/MDS was diagnosed in 106/11,952 patients (0.9%). Median time from HL treatment to t-AML/MDS was 31 months. The median age of patients with t-AML/MDS was higher than in the whole patient group (43 vs 34 years, P.0001). Patients who received 4 or more cycles of BEACOPP(escalated) had an increased risk to develop t-AML/MDS when compared with patients treated with less than 4 cycles of BEACOPP(escalated) or no BEACOPP chemotherapy (1.7% vs 0.7% vs 0.3%, P.0001). The median overall survival (OS) for all t-AML/MDS patients was 7.2 months. However, t-AML/MDS patients proceeding to allogeneic stem cell transplantation had a significantly better outcome with a median OS not reached after a median follow-up of 41 months (P.001). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|